skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

598 Total results for product and free and sample content found

Scrip

New Chugai CEO Lays Course As He Takes Reins

By Ian Haydock 25 May 2018

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.

Topic Business strategies Research

Scrip

Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More

By Jessica Merrill 25 May 2018

The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.

Topic Cancer

Scrip

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

By Brenda Sandburg 23 May 2018

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Topic Cancer

Scrip

Missing In Action: China’s Best Shot In Ebola Vaccine Race

By Brian Yang 23 May 2018

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

Topic Vaccines

Medtech Insight

Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination

22 May 2018

While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.

Topic FDA

Pink Sheet

DTC And The Art Of Selling An Establishment Pricing Plan To A Populist President

22 May 2018

The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.

Topic Drug review Drug approval

Pink Sheet

EMA Tackles Tough Job Of Filling UK Void In Working Parties

By Neena ​ Brizmohun 22 May 2018

The European Medicines Agency has started the difficult task of finding replacements for the UK chairs and members of its numerous working parties and groups who are having to vacate their position because of Brexit.

Topic Brexit

Medtech Insight

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

By Reed Miller 22 May 2018

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

Scrip

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

18 May 2018

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Topic Brexit Business strategies

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: